A randomized trial of two creams in the skin care of patients receiving radiation therapy for breast cancer in the tropics
- Conditions
- Skin reactions associated with radiation therapy for breast cancerCancer - BreastSkin - Other skin conditions
- Registration Number
- ACTRN12612000784819
- Lead Sponsor
- Townsville Health Service District
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 300
Patients undergoing radiation treatment at the Radiation Oncology Unit, The Townsville Hospital, for cancer of the breast, and who:
1. Are 18 years or older, and
2. Are able to read, write, and speak English and able to comprehend and follow the study instructions, and
3. Are willing to consent to their inclusion in the study.
Patients undergoing radiation treatment at the Radiation Oncology Unit, The Townsville Hospital, for cancer of the breast, and who:
1. Are undergoing radiation therapy for palliative reasons, and/or
2. Have specific breast lesions that receive treatment that differs significantly in terms of dosage and duration to the routine regimen, and/or
3. Have a known allergy to either Sorbolene or Cavilon cream, and/or
4. Are unable to provide their written consent owing to an intellectual or mental impairment, and/or
5. Are deemed by the Radiation Oncologist to be not suitable to be invited to participate in the study, and/or
6. Decline to participate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary Outcome: moist desquamation as assessed by nurses during treatment, and as graded by nurses from participants' description one month following treatment completion, using the CTCAEv4[Timepoint: Weekly during treatment, and 4 weeks after radiation therapy treatment completion]
- Secondary Outcome Measures
Name Time Method Secondary Outcome: Patient acceptability of the allocated cream based on a survey completed by participants[Timepoint: weekly during treatment, and one month following completion of treatment]